133 related articles for article (PubMed ID: 10529251)
1. Tallimustine lesions in cellular DNA are AT sequence-specific but not region-specific.
Herzig MC; Trevino AV; Arnett B; Woynarowski JM
Biochemistry; 1999 Oct; 38(42):14045-55. PubMed ID: 10529251
[TBL] [Abstract][Full Text] [Related]
2. The genome factor in region-specific DNA damage: the DNA-reactive drug U-78779 prefers mixed A/T-G/C sequences at the nucleotide level but is region-specific for long pure AT islands at the genomic level.
Herzig MC; Rodriguez KA; Trevino AV; Dziegielewski J; Arnett B; Hurley L; Woynarowski JM
Biochemistry; 2002 Feb; 41(5):1545-55. PubMed ID: 11814348
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial identification of a novel consensus sequence for the covalent DNA-binding polyamide tallimustine.
Sunavala-Dossabhoy G; Van Dyke MW
Biochemistry; 2005 Feb; 44(7):2510-22. PubMed ID: 15709763
[TBL] [Abstract][Full Text] [Related]
4. DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin.
Broggini M; Coley HM; Mongelli N; Pesenti E; Wyatt MD; Hartley JA; D'Incalci M
Nucleic Acids Res; 1995 Jan; 23(1):81-7. PubMed ID: 7870593
[TBL] [Abstract][Full Text] [Related]
5. Sequence-specific DNA alkylation of novel tallimustine derivatives.
Marchini S; Cozzi P; Beria I; Geroni C; Capolongo L; D'Incalci M; Broggini M
Anticancer Drug Des; 1998 Apr; 13(3):193-205. PubMed ID: 9595033
[TBL] [Abstract][Full Text] [Related]
6. Region-specific DNA damage by AT-specific DNA-reactive drugs is predicted by drug binding specificity.
Woynarowski JM; Napier C; Trevino AV; Arnett B
Biochemistry; 2000 Aug; 39(32):9917-27. PubMed ID: 10933811
[TBL] [Abstract][Full Text] [Related]
7. The alkylating antitumor drug tallimustine does not induce DNA repair.
Rossi R; Montecucco A; Capolongo L; Mezzina M; Chevallier-Lagente O; Sarasin A; Ciarrocchi G
Anticancer Res; 1996; 16(6B):3779-83. PubMed ID: 9042257
[TBL] [Abstract][Full Text] [Related]
8. Targeting critical regions in genomic DNA with AT-specific anticancer drugs.
Woynarowski JM
Biochim Biophys Acta; 2002 Jul; 1587(2-3):300-8. PubMed ID: 12084472
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationship of a series of C-terminus modified aminoalkyl, diaminoalkyl- and anilino-containing analogues of the benzoic acid mustard distamycin derivative tallimustine: synthesis, DNA binding and cytotoxicity studies.
Brooks N; Hartley JA; Simpson JE; Wright SR; Woo S; Centioni S; Fontaine MD; McIntyre TE; Lee M
Bioorg Med Chem; 1997 Aug; 5(8):1497-507. PubMed ID: 9313856
[TBL] [Abstract][Full Text] [Related]
10. Selective DNA interaction of the novel distamycin derivative FCE 24517.
Broggini M; Erba E; Ponti M; Ballinari D; Geroni C; Spreafico F; D'Incalci M
Cancer Res; 1991 Jan; 51(1):199-204. PubMed ID: 1859575
[TBL] [Abstract][Full Text] [Related]
11. Temperature influences both cytotoxicity and DNA nicking efficiency of the antitumor distamycin analogue FCE24517.
Montecucco A; Capolongo L; Melegaro G; Mondello C; Ciarrocchi G
Anticancer Res; 1994; 14(1A):189-92. PubMed ID: 8166448
[TBL] [Abstract][Full Text] [Related]
12. Effects of bizelesin (U-77779), a bifunctional alkylating minor groove agent, on genomic and simian virus 40 DNA.
Woynarowski JM; McHugh MM; Gawron LS; Beerman TA
Biochemistry; 1995 Oct; 34(40):13042-50. PubMed ID: 7548063
[TBL] [Abstract][Full Text] [Related]
13. Sequence specificity of alkylation for a series of nitrogen mustard-containing analogues of distamycin of increasing binding site size: evidence for increased cytotoxicity with enhanced sequence specificity.
Wyatt MD; Lee M; Garbiras BJ; Souhami RL; Hartley JA
Biochemistry; 1995 Oct; 34(40):13034-41. PubMed ID: 7548062
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxics derived from distamycin A and congeners.
Cozzi P; Mongelli N
Curr Pharm Des; 1998 Jun; 4(3):181-201. PubMed ID: 10197039
[TBL] [Abstract][Full Text] [Related]
15. Induction of AT-specific DNA-interstrand crosslinks by bizelesin in genomic and simian virus 40 DNA.
Woynarowski JM; Chapman WG; Napier C; Herzig MC
Biochim Biophys Acta; 1999 Feb; 1444(2):201-17. PubMed ID: 10023060
[TBL] [Abstract][Full Text] [Related]
16. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA.
Woynarowski JM; Chapman WG; Napier C; Herzig MC; Juniewicz P
Mol Pharmacol; 1998 Nov; 54(5):770-7. PubMed ID: 9804612
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, DNA binding, cytotoxicity and sequence specificity of a series of imidazole-containing analogs of the benzoic acid mustard distamycin derivative tallimustine containing an alkylating group at the C-terminus.
Brooks N; Lee M; Wright SR; Woo S; Centioni S; Hartley JA
Anticancer Drug Des; 1997 Oct; 12(7):591-606. PubMed ID: 9365504
[TBL] [Abstract][Full Text] [Related]
18. Benzoyl and cinnamoyl nitrogen mustard derivatives of benzoheterocyclic analogues of the tallimustine: synthesis and antitumour activity.
Baraldi PG; Romagnoli R; Giovanna Pavani M; del Carmen Nunez M; Bingham JP; Hartley JA
Bioorg Med Chem; 2002 May; 10(5):1611-8. PubMed ID: 11886822
[TBL] [Abstract][Full Text] [Related]
19. Alpha-bromoacryloyl derivative of distamycin A (PNU 151807): a new non-covalent minor groove DNA binder with antineoplastic activity.
Marchini S; Cirò M; Gallinari F; Geroni C; Cozzi P; D'Incalci M; Broggini M
Br J Cancer; 1999 Jun; 80(7):991-7. PubMed ID: 10362106
[TBL] [Abstract][Full Text] [Related]
20. Postlabeling detection of DNA adducts of antitumor alkylating agents.
Zhou GH; Teicher BA; Frei E
Cancer Chemother Pharmacol; 1996; 38(1):71-80. PubMed ID: 8603455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
